GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market debut of ...

At the closing bell, Metsera’s stock MTSR stood at $26.50, well above its IPO pricing level of $18. It opened on the Nasdaq ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...